# Oncolytic Herpes Simplex Virus type 1 armed with CXCL12antagonist "P2G" to disrupt CXCR4 pathway in Glioblastoma

Maxime Dubois<sup>1</sup>, Paolo D'Arrigo<sup>1</sup>, Judit Sanchez-Gil<sup>1</sup>, Cédric Lassence<sup>1</sup>, Virginie Neirinckx<sup>2</sup>, Arnaud Lombard<sup>2,3</sup> and Catherine Sadzot-Delvaux<sup>1</sup>

<sup>1</sup>Laboratory of Virology and Immunology, GIGA Infection, Inflammation and Immunity (GIGA I3), University of Liège, 4000 Liège, Belgium. <sup>2</sup>Laboratory of Nervous System Disorders and Therapy, GIGA-Neurosciences, University of Liège, 4000 Liège, Belgium. <sup>3</sup>Department of Neurosurgery, CHU of Liège, 4000 Liège, Belgium.



## Introduction

**Glioblastoma** is an aggressive high-grade astrocytoma (WHO, grade 4). Current standard treatments consist of maximal surgical resection followed by chemo-/radio-therapy.

Unfortunately, new therapies are needed as this protocol is impaired by Glioblastoma Stem-like Cells (GSCs) which promote tumour reformation and pro-tumoral microenvironment development through CXCL12/CXCR4 pathway.

In this context, stereotaxic injection of oncolytic HSV-1 (oHSV) expressing a specific CXCL12/CXCR4 pathway inhibitors (oHSV-P2G) seems to be a potent therapeutic strategy.



therapies, self-renew, leading to tumour. recurrence. In the meantime, CXCR4 pathway inhibit the immune response and promote angiogenesis.

## Materials and Methods

### Migration - Orthotopic nude mouse model

100k GB138 RFP+ cells are stereotactically engrafted in the right hemisphere of the brain (Day 0). On day 20, mice are treated with PBS, oHSV or oHSV/P2G. On day 50, 3D images are acquired by lightsheet microscopy, then TM and cc are modelized. The migration volume ratio is measured as <u>Migrating tumour cells</u> volume.

#### Tumour microenvironment - Orthotopic C57BL/6J mouse model

100k GL261N4 cells are stereotactically engrafted in the right hemisphere of the brain (Day 0). On day 7 & 14, mice are treated with PBS, oHSV or oHSV/P2G. On day 21, Cd45+ leucocytes are isolated from 12 brains per treatment and 10x genomics single-cell protocol was followed. Analysis are performed on R with Seurat.



Our previous works show that oHSV-P2G inhibits CXCR4/CXCL12 pathway, hampers tumor cells self-renewal and migration abilities.

The above results points towards an activation of adaptative lymphoid immune response, as well as a polarization of macrophages towards a pro-inflammatory and anti-angiogenic phenotype compared to PBS and oHSV. These encouraging data confirm the beneficial impact of oHSV/P2G on the tumor microenvironment.